mitoxantrone has been researched along with Edema, Pulmonary in 2 studies
Mitoxantrone: An anthracenedione-derived antineoplastic agent.
mitoxantrone : A dihydroxyanthraquinone that is 1,4-dihydroxy-9,10-anthraquinone which is substituted by 6-hydroxy-1,4-diazahexyl groups at positions 5 and 8.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Franke, M | 1 |
| Theurich, S | 1 |
| Beyer, F | 1 |
| Persigehl, T | 1 |
| Dörr, J | 1 |
| Bitsch, A | 1 |
| Schmailzl, KJ | 1 |
| Chan, A | 1 |
| von Ahsen, N | 1 |
| Hummel, M | 1 |
| Varon, R | 1 |
| Lill, CM | 1 |
| Vogel, HP | 1 |
| Zipp, F | 1 |
| Paul, F | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase II Proof of Concept Study Evaluating the Reduction of Mitoxantrone-induced Cardiotoxicity and Neurological Outcome in the Combined Use of Mitoxantrone and Dexrazoxane (Cardioxane®) in Multiple Sclerosis (MSCardioPro)[NCT01627938] | Phase 2 | 50 participants (Anticipated) | Interventional | 2012-04-30 | Active, not recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 other studies available for mitoxantrone and Edema, Pulmonary
| Article | Year |
|---|---|
[Pulmonary differentiation -/ATRA syndrome within the scope of therapy of acute promyelocytic leukemia (APL)].
Topics: Antineoplastic Combined Chemotherapy Protocols; Cytarabine; Daunorubicin; Diagnosis, Differential; D | 2014 |
Severe cardiac failure in a patient with multiple sclerosis following low-dose mitoxantrone treatment.
Topics: Adult; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Tr | 2009 |